ERAS · Erasca, Inc.
Price
Snapshot
50 fields · last close| Market Cap | $5.21B |
| P/E | — |
| Float | 303.4M |
| Beta | 0.66 |
| Volatility 30D | 60.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 60.8 |
| Price | 13.68 |
| Change | −8.25% |
| Prev Close | 14.91 |
| Open | 15.09 |
| Day Low | 14.18 |
| Day High | 15.13 |
| Avg Vol | 4 |
| Avg $ Vol | $59.05M |
| 52W High | 24.28 |
| 52W Low | 2.10 |
| 52W Pos | 52.2% |
| From High | −43.66% |
| From Low | +549.88% |
| Max DD 1Y | −59.46% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −6.97% |
| SMA 50 | −10.56% |
| SMA 200 | −9.26% |
| RSI (14) | 50.9 |
| Vol 90D | 60.1% |
| Vol 1Y | 107.5% |
| 1Y Range | 2–24 |
| Daily bars | 549 |
| Perf Week | −1.39% |
| Perf Month | +4.27% |
| Perf Quarter | −18.39% |
| Perf Half Y | +36.79% |
| Perf Year | +526.47% |
| Perf YTD | +281.06% |
| Prev Day | −8.25% |
| Clavix | C |
| Debt / Eq | 0.00 |
| Curr Ratio | 10.04 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Mixed |
| Leverage | Low |
| Sector rank | 26 / 35 |
Clavix risk grade
regraded every trading dayERAS grades C, 60.8 of 100. Steadiest on Sector Resilience (74), most exposed on Price Stability (42, fragile). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 26 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ERAS | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.66 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 60.0% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −59.5% | — |
| Typical daily movemedian absolute daily change | 2.66% | — |
| Days beyond ±3%of the last 252 sessions | 115 (46%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ERAS | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.66 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ERAS | |
|---|---|
| 1 week | −1.4% |
| 1 month | +4.3% |
| Year to date | +281.1% |
| 1 year | +526.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ERAS | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 10 Aug |
| Average score0 most bearish, 100 most bullish | 40 |
| Bullish · bearisharticles above 60 · below 40 | 10 · 20 |
| Directionarticles whose tone is improving vs worsening | 10 ↑ 20 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ERAS | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openTango Therapeutics and Erasca have opened enrollment in a Phase 1/2 study of oral vopimetostat, a drug that blocks the PRMT5 enzyme, combined with ERAS-0015, a compound designed to inhibit RAS proteins. The study targets pancreatic ductal adenocarcinoma and non-small cell lung cancer in tumors missing the MTAP gene, with the lung-cancer group also having a changed RAS gene.
Current attention on Erasca centers on a legal probe into how management described key risks for ERAS-0015, an experimental cancer drug aimed at the RAS protein family, rather than a trial result or financing. ERAS closed at $14.99, up 4.17% for the day and 10.06% over seven days, but down 17.46% over 90 days despite a roughly sevenfold one-year gain for shareholders.
ERAS traded higher at $15.41. No specific catalyst was identified.m. as Grabar Law Office issued a notice examining potential shareholder claims tied to Erasca’s public statements about ERAS-0015. The notice concerns comparisons with Revolution Medicines’ RMC-6236, intellectual-property and trade-secret risks, and April 27, 2026 disclosures containing opposing counsel’s correspondence and preliminary Phase 1 updates.
SBS Law is inviting ERAS investors with losses of at least $100,000 to join what it describes as a fraud investigation into Erasca. The article provides no findings, allegations, regulatory action, company response, or other details, so it is too limited to establish specific implications.
SBS Law is inviting ERAS investors who claim $100,000 in losses to join what it calls a fraud investigation into Erasca. The brief article provides no details about the allegations, evidence, legal claims, or Erasca's response, so it offers little substantive information beyond the solicitation.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PTCT | PTC Therapeutics, Inc. | B | $5.76B | 8.34 | 0.49 | Compare |
| CGON | CG Oncology, Inc. | B- | $6.00B | — | 0.32 | Compare |
| IONS | Ionis Pharmaceuticals, Inc. | B- | $6.67B | — | 0.36 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $3.94B | — | 0.84 | Compare |
| CELC | Celcuity Inc. | C+ | $3.39B | — | 0.19 | Compare |
| ARWR | Arrowhead Pharmaceuticals, Inc. | C+ | $8.71B | — | 1.39 | Compare |
| CYTK | Cytokinetics, Incorporated | B+ | $8.84B | — | 0.40 | Compare |
| KRYS | Krystal Biotech, Inc. | B | $9.21B | 38.12 | 0.71 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.